Patents Assigned to Bavarian Nordic A/S
-
Patent number: 7501127Abstract: The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.Type: GrantFiled: February 17, 2006Date of Patent: March 10, 2009Assignee: Bavarian Nordic A/SInventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder
-
Patent number: 7494799Abstract: The invention relates to monoparamunity inducers that are based on paramunizing viruses or viral components of a myxoma virus strain of diseased rabbits that show general symptoms of the disease. The invention also relates to a method for producing the inducers and to their use as drugs for the regulatory optimization of the paramunizing activities for use in the prophylaxis and therapy of various human and animal dysfunctions.Type: GrantFiled: January 21, 2005Date of Patent: February 24, 2009Assignee: Bavarian Nordic A/SInventors: Anton Mayr, Barbara Mayr
-
Publication number: 20090029459Abstract: The present invention relates to a method for the cultivation of primary cells. The primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The method for the cultivation of primary cells may be one step in a method for the amplification of viruses, such as poxviruses. According to this latter method the primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The cells are then infected with the virus and the infected cells are cultivated in serum free medium until progeny virus is produced.Type: ApplicationFiled: October 1, 2008Publication date: January 29, 2009Applicant: BAVARIAN NORDIC A/SInventors: INGMAR RATHE, EVA FELDER, KARL HELLER
-
Patent number: 7473536Abstract: The invention concerns an Avipoxvirus comprising in the viral genome a Vaccinia virus host range gene or a homologue of said host range gene. The invention further relates to cells, preferably avian cells, comprising a Vaccinia virus host range gene or a homologue of said host range gene. Moreover the invention concerns the use of a Vaccinia virus host range gene or an homologue thereof to increase the titer of avipoxviruses produced from cells after infection of said cells with the avipoxvirus, wherein the host range gene is expressed in said cells.Type: GrantFiled: July 29, 2003Date of Patent: January 6, 2009Assignee: Bavarian Nordic A/SInventors: Paul Howley, Christine Meisinger-Henschel
-
Patent number: 7459270Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen.Type: GrantFiled: December 4, 2007Date of Patent: December 2, 2008Assignee: Bavarian Nordic A/SInventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel
-
Patent number: 7445924Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.Type: GrantFiled: March 3, 2005Date of Patent: November 4, 2008Assignee: Bavarian Nordic A/SInventors: Paul Chaplin, Paul Howley, Christine Meisinger, Ingmar Rathe, Eva Felder, Karl Heller
-
Patent number: 7384644Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by induction of protective immunity against a lethal vaccinia virus infection in a mouse, whereby the effective amount of the MVA-BN virus, or a derivative thereof, required to confer said immunity is less than the effective amount of MVA-575 required to render said mouse immune to a lethal vaccinia virus infection, and/or the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.Type: GrantFiled: August 5, 2005Date of Patent: June 10, 2008Assignee: Bavarian Nordic A/SInventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel
-
Publication number: 20080089907Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen.Type: ApplicationFiled: December 4, 2007Publication date: April 17, 2008Applicant: BAVARIAN NORDIC A/SInventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel
-
Patent number: 7338662Abstract: The sent invention relates to a recombinant poxvirus vector capable of expressing two or more homologous, foreign sequences, which derive from different variants of a microorganism, and which have a homology of 50% or above. The invention further relates to a method for preparing such recombinant poxvirus and the use of such recombinant poxvirus as medicament or vaccine. Additionally, a method for affecting preferably inducing, an immune response in a living animal, including a human, is provided.Type: GrantFiled: May 14, 2003Date of Patent: March 4, 2008Assignee: Bavarian Nordic A/SInventors: Paul Howley, Sonja Leyrer
-
Patent number: 7335364Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen.Type: GrantFiled: August 23, 2006Date of Patent: February 26, 2008Assignee: Bavarian Nordic A/SInventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel
-
Patent number: 7300658Abstract: Recombinant poxvirus are disclosed comprising in the viral genome at least two expression cassettes, each comprising a cowpox ATI promoter according to SEQ ID NO:1, a polynucleotide sequence in which not more than 6 nucleotides are substituted, deleted, and/or inserted into SEQ ID NO:1 and still active as an ATI promoter, or a polynucleotide comprising at least 10 nucleotides including nucleotides 22 to 29 of SEQ ID NO: 1 and still active as an ATI promoter and a coding sequence, wherein the expression of the coding sequence is regulated by said promoter or said polynucleotides. The recombinant poxviruses are useful as pharmaceutically active ingredients in the preparation of vaccines.Type: GrantFiled: November 12, 2003Date of Patent: November 27, 2007Assignee: Bavarian Nordic A/SInventors: Paul Howley, Sonja Leyrer
-
Patent number: 7189536Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen.Type: GrantFiled: May 16, 2003Date of Patent: March 13, 2007Assignee: Bavarian Nordic A/SInventors: Paul Chaplin, Paul Howley, Christine Meisinger
-
Publication number: 20060280758Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen.Type: ApplicationFiled: August 23, 2006Publication date: December 14, 2006Applicant: BAVARIAN NORDIC A/SInventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel
-
Patent number: 7097842Abstract: The invention concerns the use of a virus for the preparation of a medicament for the vaccination, treatment, or protection, of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara. In particular, the invention concerns the vaccination of neonates against infections with viruses belonging the same virus group as the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumor antigens, wherein the tumor antigen and/or the foreign antigen are different from the antigens associated with the virus.Type: GrantFiled: April 18, 2003Date of Patent: August 29, 2006Assignee: Bavarian Nordic A/SInventors: Mark Suter, Sabine Vollstedt, Paul Chaplin
-
Patent number: 7094412Abstract: The present invention relates to a formulation, in particular an aqueous formulation comprising (i) a poxvirus of one of the genera orthopoxvirus, avipoxvirus, parapoxvirus, capripoxvirus and suipoxvirus, (ii) a disaccharide, (iii) a pharmaceutically acceptable polymer and optionally (iv) a buffer. The aqueous formulation is particularly suitable for freeze drying processes resulting in a stable, freeze-dried, poxvirus containing composition. The invention further concerns a method for preparing a freeze-dried, poxvirus containing composition and the thus obtained product.Type: GrantFiled: November 28, 2002Date of Patent: August 22, 2006Assignee: Bavarian Nordic A/SInventors: Paul Howley, Karl Heller, Ingmar Räthe
-
Patent number: 7083607Abstract: The invention relates to an injection device containing a hollow needle (1), a cutting needle that can be inserted into the hollow needle and that has a cutting tip projecting from the front end of the hollow needle, a catheter (9) that replaces said cutting needle and that can be inserted approximately up to its front end into the hollow needle (9), said catheter having a receiving chamber (30) for a substance in the form of a capsule on its distal end, in addition to a mandrin (29) that can be inserted into the catheter (9) and which can be placed in a position defining a receiving chamber (30) filled with capsules (22) on the distal end of said catheter, wherein the capsules (22) contained in the receiving chamber (30) of the inserted catheter (9) are released without exerting any pressure in the target area of the body (23) once the injection device has been arranged in a target area of a body (23) by relatively pulling back both the catheter (9) and the hollow needle (1) in relation to the mandrin (29) aType: GrantFiled: July 12, 2002Date of Patent: August 1, 2006Assignee: Bavarian Nordic A/SInventors: Matthias Löhr, Walter Günzburg
-
Publication number: 20060127984Abstract: The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara. In particular, the invention concerns the vaccination of neonates against infections with viruses belonging to the same virus group than the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumour antigens, wherein the tumour antigen and/or the foreign antigen are different from the antigens associated with the virus.Type: ApplicationFiled: January 27, 2006Publication date: June 15, 2006Applicant: BAVARIAN NORDIC A/SInventors: Mathias Ackermann, Mark Suter, Hans Hefti, Marco Franchini, Sabine Vollstedt, Paul Chaplin
-
Patent number: 7056723Abstract: The present invention relates to a method for the recovery of poxviruses, in particular modified Vaccinia virus Ankara (MVA), from infected cells. According to the present invention the virus-infected cells are subjected to a high-pressure homogenization to obtain a virus containing homogenate. The virus containing homogenate can be subjected to at least one purification step to obtain apoxvirus-enriched fraction. The invention further relates to the virus containing fraction and the virus containing homogenate obtained by the method according to the present invention.Type: GrantFiled: December 13, 2002Date of Patent: June 6, 2006Assignee: Bavarian Nordic A/SInventors: Karl Heller, Jutta Kramer
-
Publication number: 20050214324Abstract: The present invention relates to a method for the cultivation of primary cells. The primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The method for the cultivation of primary cells may be one step in a method for the amplification of viruses, such as poxviruses. According to this latter method the primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The cells are then infected with the virus and the infected cells are cultivated in serum free medium until progeny virus is produced.Type: ApplicationFiled: March 3, 2005Publication date: September 29, 2005Applicant: BAVARIAN NORDIC A/SInventors: Ingmar Rathe, Eva Felder, Karl Heller
-
Patent number: 6924137Abstract: The present invention relates to a process for producing poxvirus, in particular Chordopoxvirus, wherein the poxvirus is cultivated at a temperature below 37° C. The process leads to increased virus propagation at the decreased temperature.Type: GrantFiled: July 2, 2002Date of Patent: August 2, 2005Assignee: Bavarian Nordic A/SInventors: Paul Howley, Karl Heller, Ingmar Räthe